For the year ending 2025-12-31, CADL has $125,195K in assets. $73,273K in debts. $119,731K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 119,731 | |||
| Prepaid expenses and other current assets | 1,658 | |||
| Total current assets | 121,389 | |||
| Total fixed assets | 5,200 | |||
| Less accumulated depreciation | 3,558 | |||
| Fixed assets, net | 1,642 | |||
| Lease right of use assets | 1,661 | |||
| Restricted cash | 416 | |||
| Other assets | 87 | |||
| Total assets | 125,195 | |||
| Accounts payable | 1,129 | |||
| Accrued expenses | 7,334 | |||
| Current portion of term loans | 0 | |||
| Current portion of lease liability | 445 | |||
| Warrant liabilities | 0 | |||
| Other current liabilities | 89 | |||
| Total current liabilities | 8,997 | |||
| Deferred revenue | 89 | |||
| Term loans, net of current portion | 46,122 | |||
| Other long-term debt | 1,008 | |||
| Lease liability, net of current portion | 1,459 | |||
| Warrant liabilities | 15,598 | |||
| Total liabilities | 73,273 | |||
| Common stock, 0.01 par value 150,000,000 shares authorized at december 31, 2025 and 2024 55,020,911 and 46,933,088 shares issued at december 31, 2025 and 2024, respectively and 54,898,303 and 46,810,480 shares outstanding at december 31, 2025 and 2024, respectively | 550 | |||
| Treasury stock (at cost) | 448 | |||
| Additional paid-in capital | 282,207 | |||
| Accumulated deficit | -230,387 | |||
| Total stockholders' equity | 51,922 | |||
| Total liabilities and stockholders' equity | 125,195 | |||
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)